晚期非小細(xì)胞癌治療李田(編輯修改稿)
2025-07-13 00:53 本頁(yè)面
【文章內(nèi)容簡(jiǎn)介】 是唯一影響吉西他濱療效的因子 ? 臨床研究也顯示 RRM1的表達(dá)情況可以預(yù)測(cè)吉西他濱的療效 ? 低表達(dá)者療效好，高表達(dá)者療效差 ( vs ) Rosell R, et al. Clin Cancer Res, 2022, 10:13181325. Bepler G, et al. J Clin Oncol, 2022, 24:377s. RRM1 (Ribonucleotide Reductase M1) ：核苷酸還原酶調(diào)節(jié)因子 1 Ribonucleotide Reductase Messenger RNA Expression and Survival in GemcitabineCisplatinTreated Advanced NonSmall Cell Lung Cancer Patients — Clinical Cancer Research 原文： A, survival for patients treated with gemcitabine plus cisplatin. Median survival was significantly longer in the gemcitabine/cisplatin arm among patients with low RRM1 levels. Median survival was months (95% CI, – months) for patients with low levels and months (95% CI, 0– months) for those with high levels (P = 。 Fig. 2A ) D, time to progression for patients treated with gemcitabine plus cisplatin Median time to progression was significantly longer in the gemcitabine/cisplatin arm among patients with low RRM1 levels. Median time to progression was months (95% CI, – months) for patients with low levels and months (95% CI, – months) for those with high levels (P = 。 Fig. D). NCCN資料顯示：
教學(xué)教案相關(guān)推薦
鄂ICP備17016276號(hào)-1